^
    Apply
    Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer (NCT02520063)
    Phase 1/2
    University of Alabama at Birmingham
    Active, not recruiting
    Last update posted :
    12/27/2024
    Initiation :
    02/23/2019
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    HER-2
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    everolimus • letrozole • carotuximab IV (ENV-105)
    Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) (NCT05061017)
    Phase 2
    Diwakar Davar
    Completed
    Last update posted :
    06/04/2024
    Initiation :
    12/09/2021
    Primary completion :
    02/05/2024
    Completion :
    03/18/2024
    KRAS • BRAF • ALK • MET
    |
    KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RAS wild-type
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cyclophosphamide • cyclophosphamide intravenous • pixatimod (PG545)
    Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer (NCT05401110)
    Phase 1
    Karen Reckamp, MD, MS
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    09/15/2023
    Primary completion :
    01/01/2025
    Completion :
    01/01/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib) • carotuximab IV (ENV-105)
    NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors (NCT05661201)
    Phase 1
    Georgetown University
    Recruiting
    Last update posted :
    03/11/2024
    Initiation :
    04/12/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    KRAS • ST2
    |
    KRAS mutation
    |
    doxorubicin hydrochloride • Nerofe (84AA-API 14AA)
    Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent (NCT06075849)
    Phase 1
    Panolos Bioscience
    Recruiting
    Last update posted :
    02/23/2024
    Initiation :
    10/25/2023
    Primary completion :
    10/01/2024
    Completion :
    01/01/2025
    FLT1
    |
    PB101
    A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer (NCT05318443)
    Phase 3
    Shanghai Institute Of Biological Products
    Completed
    Last update posted :
    12/27/2023
    Initiation :
    04/17/2020
    Primary completion :
    12/26/2022
    Completion :
    01/12/2023
    EGFR • ALK • ROS1
    |
    ALK positive • ROS1 positive
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • SIBP-04 (bevacizumab biosimilar)
    VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) (NCT04166383)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    11/08/2023
    Initiation :
    08/09/2020
    Primary completion :
    04/12/2022
    Completion :
    12/31/2022
    KRAS
    |
    KRAS wild-type • RAS wild-type
    |
    Opdivo (nivolumab) • ofranergene obadenovec (VB-111)
    Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (NCT03161652)
    Phase 2
    Carmen Clapp
    Recruiting
    Last update posted :
    08/25/2023
    Initiation :
    05/24/2017
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    PRL
    |
    Lucentis (ranibizumab)
    Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML (NCT04365179)
    Phase 1b
    Immune System Key Ltd
    Recruiting
    Last update posted :
    07/22/2022
    Initiation :
    06/18/2020
    Primary completion :
    12/30/2022
    Completion :
    12/30/2022
    ST2
    |
    Nerofe (84AA-API 14AA)
    Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer (NCT03634150)
    Phase 1b
    Immune System Key Ltd
    Withdrawn
    Last update posted :
    10/26/2021
    Initiation :
    09/06/2018
    Primary completion :
    04/21/2020
    Completion :
    04/21/2020
    ST2
    |
    doxorubicin hydrochloride • Nerofe (84AA-API 14AA)
    A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS (NCT03059615)
    Phase 2a
    Immune System Key Ltd
    Withdrawn
    Last update posted :
    07/31/2020
    Initiation :
    10/25/2018
    Primary completion :
    07/26/2020
    Completion :
    07/26/2020
    ST2
    |
    doxorubicin hydrochloride • Nerofe (84AA-API 14AA)
    Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC (NCT03181308)
    Phase 1b
    Tracon Pharmaceuticals Inc.
    Completed
    Last update posted :
    06/24/2020
    Initiation :
    11/09/2017
    Primary completion :
    07/22/2019
    Completion :
    07/22/2019
    EGFR • PD-L1 • ROS1 • ALK1
    |
    Opdivo (nivolumab) • carotuximab IV (ENV-105)
    A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma (NCT01975519)
    Phase 2a
    Tracon Pharmaceuticals Inc.
    Completed
    Last update posted :
    05/20/2020
    Initiation :
    12/10/2013
    Primary completion :
    03/11/2019
    Completion :
    03/11/2019
    ENG
    |
    pazopanib • carotuximab IV (ENV-105)
    Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC (NCT03780010)
    Phase 1b
    Tracon Pharmaceuticals Inc.
    Completed
    Last update posted :
    10/28/2019
    Initiation :
    09/01/2015
    Primary completion :
    06/01/2019
    Completion :
    06/01/2019
    ALK1
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • carotuximab IV (ENV-105)
    Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer (NCT01326481)
    Phase 1b
    Tracon Pharmaceuticals Inc.
    Completed
    Last update posted :
    03/18/2019
    Initiation :
    06/01/2011
    Primary completion :
    09/01/2014
    Completion :
    12/01/2014
    HER-2
    |
    HER-2 negative
    |
    capecitabine • carotuximab IV (ENV-105)
    Sorafenib and TRC105 in Hepatocellular Cancer (NCT01306058)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    01/23/2019
    Initiation :
    02/11/2011
    Primary completion :
    06/01/2016
    Completion :
    06/09/2017
    ENG
    |
    sorafenib • carotuximab IV (ENV-105)
    Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated (NCT01332721)
    Phase 1b
    Tracon Pharmaceuticals Inc.
    Completed
    Last update posted :
    12/05/2018
    Initiation :
    04/01/2011
    Primary completion :
    09/01/2012
    Completion :
    12/01/2013
    MUC16
    |
    Avastin (bevacizumab) • carotuximab IV (ENV-105)
    Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer (NCT01727089)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    08/28/2018
    Initiation :
    11/01/2012
    Primary completion :
    08/08/2017
    Completion :
    08/08/2017
    IL2
    |
    Avastin (bevacizumab) • carotuximab IV (ENV-105)
    Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies (NCT01690741)
    Phase 1
    Immune System Key Ltd
    Completed
    Last update posted :
    06/25/2018
    Initiation :
    12/01/2013
    Primary completion :
    12/19/2017
    Completion :
    12/19/2017
    ST2
    |
    Nerofe (84AA-API 14AA)
    Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NCT00454194)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Completed
    Last update posted :
    03/21/2017
    Initiation :
    09/01/2007
    Primary completion :
    07/01/2010
    Completion :
    05/01/2013
    FLT1
    |
    sorafenib • pemetrexed
    Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma (NCT01757652)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    10/07/2015
    Initiation :
    12/01/2012
    Primary completion :
    01/01/2100
    ENG
    |
    carotuximab IV (ENV-105)